3. #WorldCancerDay The greatest incidence of AMI in cancer pts is within 30d of Ca diagnosis, many treatments can ⬆️risk aswell as shared risk factors. We sought to study whether STEMI pts with cancer are less likley to get PPCI & whether they benefit academic.oup.com/ehjacc/advance…
4. #WorldCancerDay We used a propensity score matching approach to calculate the average treatment effect of PPCI in 5 cancers types (haematological, breast, colon, prostate and lung) and compare it to pts without cancer. Cancer pts upto 50% less likely to get PPCI @mirvatalasnag
6. #WorldCancerDay Why are pts with cancer less likely to get PPCI?
🥕⬆️bleeding risk: ⬇️Clotting , low platelets, bone marrow suppression
🥕 more co-morbid
🥕 Physician bias re expected benefit, with cancer pts excluded from RCTs
🥕 ⬆️ risk of thrombotic events @mirvatalasnag
7. #WorldCancerDay what can we do to optimise outcomes during / post PPCI?
🥕 Consider / bleeding vs ischemic risk. Colon Ca⬆️bleeding, Lung CA ⬆️ischemic
🥕 #radialfirst
🥕 OCT/Image #imagefirst
🥕 use stent platforms that only require short dapt
🥕 short dapt with longer p2y12
1. Clickbait title but content worth discussing- my thoughts over the next few tweets
➡️Questions around AMI definition.
Dr Taggart and others were part of the discussions that agreed to AMI definition. I think it was right because- see2. medscape.com/viewarticle/93… via @medscape
2. an endpoint should have same prognostic impact in each trial arm. EXCEL definition does, UDMI doesnt
however:
➡️Should probably only include spontaneous AMI post procedure (>72 hrs), whatever definition you use, CABG better in long term
3. ➡️I personally dont think perceived COI have had any impact on the running / outcomes of the trial. Without industry support this trial would never have happened, nor would have many other fundamental trials. This is a smoke screen
1. My talk today at #SHA2020 surgeon session re what #EXCEL really shows. To begin- need to understand importance of endpoints
➡️clinically relevant
➡️related to intervention
➡️relevant to pt
➡️similar prognostic impact in each arm @SVRaoMD@ajaykirtane@RodrigoBagur@jedicath
2. A significant proportion of LMS wont be suitable for either surgery / CABG. As heart teams we have to do better in stratifying by extent of disease - 1/4 of pts included in #EXCEL didnt meet inclusion criteria (low/ intermediate risk) @ovidiogarciav@aspergian1@cardioPCImom
3. The question of periporcedural AMI definition- depends on how you define re UDMI or protocol definition, will impact whether CABG 2x greater or 1/3 less. Personally i think protocol definition better as prognostic impact of AMI the same then in both arms (see pt 1)- BUT ➡️
1. Our analysis of >70,000 pts with rheumatological disease undergoing pci (RA, SLA, SSC) led by @saraceciliamtz and @dr_mosama with collobaration with rheumatologists. 1.4% of pts have rheumaological diseases @DocSavageTJU@adityadoc1@RodrigoBagur RA increasing over time
3. Summary slide. Analyses of nationwide databases provide a real- world vantage of outcomes on performed procedures, supplementing controlled trials and prospective cohorts and often answering questions on populations excluded from trials or at low prevalence. @mirvatalasnag
1. My Big Data talk in pci at #ICI18 meeting in Tel Aviv. Guidelines tell us to take comorbidity, cancer, frailty into account to guide practice, but not found in contemporary risk scores. Data from EHR can help guide. @DrMauricioCohen@Uqayyum123@SmithElliotjs@jodiel0ve
2. Cardiologists have narrow view of comorbidity. consider individual conditions & not global comorbid burden. Non-CV death and readmissions more common than CV death following PCI. Driven by comorbidity. @mirvatalasnag@akhojaMD@Dralkutshan@jedicath@MBalghith@DocSavageTJU
3. Global comorbid burden such as Charlson, Elixhouser provide important prognostic information for PCI. 1 in 10 pts in PCI have a current or prior hx of cancer, yet we dont use any of this information in our risk models / to guide decisions. Unmet Need @DrFernandoCohen